Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
In order to achieve the treatment of chronic hepatitis C with a nucleic acid, the present study aimed at new development of nucleic acid drugs and DDS for the purpose of treatment of fibrosis and rejection of HCV. To establish a modified exosomes producing cell, the envelope expression vector of HCV and to prepare a packaging vector. Modified exosomes that were established in this study, it is possible that the beginning can be widely used for the treatment of chronic hepatitis C as a DDS for delivering efficient pharmaceutical into hepatocytes. Also packaging system enclosing the efficient nucleic acid medicine to a modified exosomes are expected to promote the realization of the nucleic acid drugs.
|